The study group included 117 patients with RR-CLL (with early relapse after immunochemotherapy or bearing TP53 aberrations) treated with VEN-R in 2019-2023 outside clinical trials. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.